A team of researchers led by Duke Cancer Institute have identified key events that prompt certain cancer cells to develop resistance to otherwise lethal therapies.  By mapping the points of epigenetic methylation that cells of melanoma, breast cancer and a blood cancer called myelofibrosis use to become resistant to drugs, the researchers now have much better targets for blocking those pathways and keeping current therapies … Continue reading Researchers begin to map epigenetic methylation in specific cancer drug resistance.